HF
BDRX

HRT Financial’s Biodexa Pharmaceuticals BDRX Stock Holding History

HRT Financial’s Portfolio BDRX Stock Details BDRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,117
Closed -$24K – 3801
2025
Q4 		$24K Buy
+2,117
New +$60.2K ﹤0.01% 2965
2020
Q4 		– Hold
0
– -$33K – 1857
2020
Q3 		– Hold
0
– – – 1732

Other funds holding BDRX

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
HHCP
Hilton Head Capital Partners Hilton Head Island, South Carolina $198M AUM
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

HRT Financial's BDRX Position: Q1 2026 in Review

HRT Financial sold out of Biodexa Pharmaceuticals (BDRX) in Q1 2026, closing a stake of 2,117 shares — an estimated $24K sold.

HRT Financial first reported a position in BDRX in Q4 2025 and held it in 1 quarter. The position peaked at $24K in Q4 2025. 7 funds tracked by Wall St. Rank hold BDRX as of Q1 2026.

  • HRT Financial reported no remaining Biodexa Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • HRT Financial sold 2,117 Biodexa Pharmaceuticals shares in Q1 2026, an estimated $24K.
  • HRT Financial first reported a position in Biodexa Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • HRT Financial's Biodexa Pharmaceuticals position peaked at $24K in Q4 2025.
  • 7 funds tracked by Wall St. Rank held Biodexa Pharmaceuticals as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.